<?xml version='1.0' encoding='utf-8'?>
<document id="22821721"><sentence text="Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study."><entity charOffset="86-95" id="DDI-PubMed.22821721.s1.e0" text="glipizide" /><entity charOffset="97-107" id="DDI-PubMed.22821721.s1.e1" text="cilostazol" /><entity charOffset="134-157" id="DDI-PubMed.22821721.s1.e2" text="3, 4-dehydro-cilostazol" /><pair ddi="false" e1="DDI-PubMed.22821721.s1.e0" e2="DDI-PubMed.22821721.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22821721.s1.e0" e2="DDI-PubMed.22821721.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s1.e0" e2="DDI-PubMed.22821721.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s1.e1" e2="DDI-PubMed.22821721.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s1.e1" e2="DDI-PubMed.22821721.s1.e2" /></sentence><sentence text="A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the simultaneous quantitation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in rat plasma was developed and validated"><entity charOffset="134-143" id="DDI-PubMed.22821721.s2.e0" text="glipizide" /><entity charOffset="145-155" id="DDI-PubMed.22821721.s2.e1" text="cilostazol" /><entity charOffset="160-183" id="DDI-PubMed.22821721.s2.e2" text="3, 4-dehydro-cilostazol" /><pair ddi="false" e1="DDI-PubMed.22821721.s2.e0" e2="DDI-PubMed.22821721.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22821721.s2.e0" e2="DDI-PubMed.22821721.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s2.e0" e2="DDI-PubMed.22821721.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s2.e1" e2="DDI-PubMed.22821721.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s2.e1" e2="DDI-PubMed.22821721.s2.e2" /></sentence><sentence text=" Glimepride was used as an internal standard (IS)"><entity charOffset="1-11" id="DDI-PubMed.22821721.s3.e0" text="Glimepride" /></sentence><sentence text=" The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×4" /><sentence text="6 mm i" /><sentence text=" d" /><sentence text=", 5 µ) using acetonitrile: 2 mM ammonium acetate buffer, pH 3"><entity charOffset="13-25" id="DDI-PubMed.22821721.s7.e0" text="acetonitrile" /></sentence><sentence text="2 (90:10, v/v) as mobile phase at a flow rate 0" /><sentence text="4 mL/min in an isocratic mode" /><sentence text=" Selective reaction monitoring was performed using the transitions m/z 446" /><sentence text="4&gt;321" /><sentence text="1, 370" /><sentence text="2&gt;288" /><sentence text="3, 368" /><sentence text="3&gt;286" /><sentence text="2, and 491" /><sentence text="4&gt;352" /><sentence text="2 to quantify glipizide, cilostazol, 3, 4-dehydro-cilostazol and glimepride, respectively"><entity charOffset="14-23" id="DDI-PubMed.22821721.s18.e0" text="glipizide" /><entity charOffset="25-35" id="DDI-PubMed.22821721.s18.e1" text="cilostazol" /><entity charOffset="37-60" id="DDI-PubMed.22821721.s18.e2" text="3, 4-dehydro-cilostazol" /><entity charOffset="65-75" id="DDI-PubMed.22821721.s18.e3" text="glimepride" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e0" e2="DDI-PubMed.22821721.s18.e0" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e0" e2="DDI-PubMed.22821721.s18.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e0" e2="DDI-PubMed.22821721.s18.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e0" e2="DDI-PubMed.22821721.s18.e3" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e1" e2="DDI-PubMed.22821721.s18.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e1" e2="DDI-PubMed.22821721.s18.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e1" e2="DDI-PubMed.22821721.s18.e3" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e2" e2="DDI-PubMed.22821721.s18.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s18.e2" e2="DDI-PubMed.22821721.s18.e3" /></sentence><sentence text=" Calibration curves were constructed over the range of 25-2 000 ng/mL for glipizide, cilostazol and 3, 4-dehydro-cilostazol"><entity charOffset="74-83" id="DDI-PubMed.22821721.s19.e0" text="glipizide" /><entity charOffset="85-95" id="DDI-PubMed.22821721.s19.e1" text="cilostazol" /><entity charOffset="100-123" id="DDI-PubMed.22821721.s19.e2" text="3, 4-dehydro-cilostazol" /><pair ddi="false" e1="DDI-PubMed.22821721.s19.e0" e2="DDI-PubMed.22821721.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22821721.s19.e0" e2="DDI-PubMed.22821721.s19.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s19.e0" e2="DDI-PubMed.22821721.s19.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s19.e1" e2="DDI-PubMed.22821721.s19.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s19.e1" e2="DDI-PubMed.22821721.s19.e2" /></sentence><sentence text=" The lower limit of quantitation was 25 ng/mL for all the analytes" /><sentence text=" The recoveries from spiked control samples were&gt;76% for all analytes and internal standard" /><sentence text=" Intra and inter day accuracy and precision of validated method were within the acceptable limits of at all concentration" /><sentence text=" The quantitation method was successfully applied for simultaneous estimation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in a pharmacokinetic drug-drug interaction study in wistar rats"><entity charOffset="81-90" id="DDI-PubMed.22821721.s23.e0" text="glipizide" /><entity charOffset="92-102" id="DDI-PubMed.22821721.s23.e1" text="cilostazol" /><entity charOffset="107-130" id="DDI-PubMed.22821721.s23.e2" text="3, 4-dehydro-cilostazol" /><pair ddi="false" e1="DDI-PubMed.22821721.s23.e0" e2="DDI-PubMed.22821721.s23.e0" /><pair ddi="false" e1="DDI-PubMed.22821721.s23.e0" e2="DDI-PubMed.22821721.s23.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s23.e0" e2="DDI-PubMed.22821721.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22821721.s23.e1" e2="DDI-PubMed.22821721.s23.e1" /><pair ddi="false" e1="DDI-PubMed.22821721.s23.e1" e2="DDI-PubMed.22821721.s23.e2" /></sentence><sentence text="" /></document>